Article Text

PDF

Potentially serious side-effects of high-dose twice-weekly rifampicin
  1. Graham Poole,
  2. Peter Stradling,
  3. Sheila Worlledge

    Abstract

    Daily rifampicin in a single dose of 600 mg, combined with other drugs, usually streptomycin and isoniazid, was given to forty-nine patients for 3 months. It was planned to continue for another 15 months with twice-weekly rifampicin 1200 mg plus isoniazid 900 mg, but the high incidence of side effects led to cessation of the intermittent regimen when only two patients had completed 18 months.

    Though there was no serious problem with daily treatment, eleven patients (22%) were unable to continue rifampicin on the intermittent regimen. In eight (16%) a pyrexial syndrome occurred. In one of these patients there was also temporary renal failure and in another, precipitous thrombocytopenia led to epistaxis and bleeding into the tongue and lips. Symptomless thrombocytopenia developed in two other patients, making three cases (6%) of thrombocytopenia in all.

    In sixteen (33%) of the forty-nine patients antibodies to rifampicin were detected in the blood. Side-effects occurred in nine (56%) of these, including the three developing thrombocytopenia, but in only two (6%) of the thirty-three patients with no antibodies detected. This association of toxic reactions with antibodies is highly significant (P < 0·001).

    Statistics from Altmetric.com

    Footnotes

    • * This article is reprinted from the British Medical Journal (1971) 3, 343-347, by kind permission of the Editor,

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.